AC Immune Stock FY 2025 Results: Eyeing ACI-7104 Catalysts (NASDAQ:ACIU)

AC Immune SA ( ACIU ) reported a FY25 GAAP EPS loss of CHF 0.70. Again, we saw continued losses typical of a clinical-stage biotech company. However, what was concerning was that revenue cameI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges ...